Literature DB >> 29978463

The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.

Kiki M H Vangangelt1, Lisanne S A Tollenaar1, Gabi W van Pelt1, Esther M de Kruijf1, Tim J A Dekker1, Peter J K Kuppen1, Rob A E M Tollenaar1, Wilma E Mesker1.   

Abstract

The tumor-stroma ratio (TSR) has previously been found to be a strong prognostic parameter in primary breast cancer tumors. Since the presence of tumor cells in lymph nodes is important for clinical decision making, the influence of TSR in the primary breast tumor combined with the TSR in tumor-positive lymph nodes on prognosis was evaluated. Women with invasive breast cancer without distant metastasis who underwent an axillary lymph node dissection between 1985 and 1994 at the Leiden University Medical Center were retrospectively analyzed. TSR assessment was performed on hematoxylin and eosin stained tissue slides. In total, 87 (45.5%) primary tumors were scored as stroma-low and 104 (54.5%) as stroma-high. Patients with a high stromal percentage in the primary tumors had a statistically significant worse relapse free period (RFP) compared to stroma-low tumors (HR 1.97, 95% CI 1.37-2.82, p < 0.001). A total number of 915 lymph nodes were assessed for TSR. In 101 (52.9%) patients, heterogeneity was observed between stroma percentage category in primary tumor and lymph nodes. The combination of TSR of the primary tumor combined with TSR of tumor-positive lymph nodes strengthened each other as independent prognostic parameter for RFP (p = 0.019). Patients with primary tumor stroma-low/lymph nodes stroma-low tumors showed strongly improved RFP rates compared to patients with primary tumor stroma-high/lymph node stroma-high tumors with 10-year percentages of 58 versus 8%, respectively. Assessing the TSR on tumor-positive lymph nodes can provide additional prognostic information. Stromal activation strongly differs between primary tumors and lymph node metastasis.
© 2018 UICC.

Entities:  

Keywords:  breast cancer; lymph nodes; prognosis; tumor-stroma ratio

Mesh:

Year:  2018        PMID: 29978463     DOI: 10.1002/ijc.31658

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

Review 1.  Standardization of the tumor-stroma ratio scoring method for breast cancer research.

Authors:  Sophie C Hagenaars; Kiki M H Vangangelt; Gabi W Van Pelt; Zsófia Karancsi; Rob A E M Tollenaar; Andrew R Green; Emad A Rakha; Janina Kulka; Wilma E Mesker
Journal:  Breast Cancer Res Treat       Date:  2022-04-16       Impact factor: 4.624

2.  Tumor stroma as contributing factor in the lymph node metastases process?

Authors:  Wilma E Mesker; Gabi W van Pelt; Rob A E M Tollenaar
Journal:  Oncotarget       Date:  2019-01-29

Review 3.  Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy.

Authors:  Jenniffer Linares; Juan A Marín-Jiménez; Jordi Badia-Ramentol; Alexandre Calon
Journal:  Front Cell Dev Biol       Date:  2021-01-22

4.  Tumour Stroma Ratio Assessment Using Digital Image Analysis Predicts Survival in Triple Negative and Luminal Breast Cancer.

Authors:  Ewan Ka Millar; Lois H Browne; Julia Beretov; Kirsty Lee; Jodi Lynch; Alexander Swarbrick; Peter H Graham
Journal:  Cancers (Basel)       Date:  2020-12-13       Impact factor: 6.639

5.  The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer.

Authors:  Cor J Ravensbergen; Matthew Kuruc; Meaghan Polack; Stijn Crobach; Hein Putter; Hans Gelderblom; Devjit Roy; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cancers (Basel)       Date:  2021-12-29       Impact factor: 6.639

6.  Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.

Authors:  Cor J Ravensbergen; Meaghan Polack; Jessica Roelands; Stijn Crobach; Hein Putter; Hans Gelderblom; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

7.  Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer.

Authors:  Meiting Fu; Dexin Chen; Fuzheng Luo; Mengshu Li; Yadong Wang; Junsheng Chen; Aimin Li; Side Liu
Journal:  Br J Cancer       Date:  2019-12-02       Impact factor: 7.640

8.  Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms.

Authors:  Floriane Pelon; Brigitte Bourachot; Yann Kieffer; Ilaria Magagna; Fanny Mermet-Meillon; Isabelle Bonnet; Ana Costa; Anne-Marie Givel; Youmna Attieh; Jorge Barbazan; Claire Bonneau; Laetitia Fuhrmann; Stéphanie Descroix; Danijela Vignjevic; Pascal Silberzan; Maria Carla Parrini; Anne Vincent-Salomon; Fatima Mechta-Grigoriou
Journal:  Nat Commun       Date:  2020-01-21       Impact factor: 14.919

Review 9.  Chemotherapy resistance and stromal targets in breast cancer treatment: a review.

Authors:  Y M van der Spek; J R Kroep; R A E M Tollenaar; Wilma E Mesker
Journal:  Mol Biol Rep       Date:  2020-10-01       Impact factor: 2.316

10.  The prognostic value of tumor budding in laryngeal squamous cell carcinoma.

Authors:  Heng Zhang; Xiaoli Sheng; Siyi Zhang; Xia Gu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.